
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More